山東新華製藥股份(00719.HK)與藥物所簽訂創新藥物“LXH-2201原料藥及其製劑”的技術轉讓(專利權)合同
格隆匯7月4日丨山東新華製藥股份(00719.HK)發佈公吿,鑑於中國醫學科學院藥物研究所(“藥物所”)擁有的創新藥物LXH-2201項目的臨牀前研究和I期臨牀試驗研究已經完成,公司將出資人民幣1億元受讓該項目,並與藥物所就該項目進行合作。近日,公司與藥物所簽訂了關於創新藥物“LXH-2201原料藥及其製劑”的《技術轉讓(專利權)合同》。
本合同簽訂後該項目的所有費用由公司支付,在支付完合同約定款後,新華製藥將成為“LXH-2201”創新藥物中國相關專利的專利權人。新華製藥有權利用藥物所讓與的技術進行後續改進,由此產生的具有實質性或者創造性技術進步特徵的新的技術成果,歸新華製藥所有。“LXH-2201”若取得生產批文,則歸新華製藥所有。
該創新藥物的研究將為心腦血管系統疾病患者提供更安全有效的治療選擇,本次公司與藥物所簽署《技術轉讓(專利權)合同》,符合公司長期發展戰略,有利於豐富公司1類創新藥物研發管線,增強公司的創新藥物研發能力,提升藥品臨牀試驗能力,同時也有利於增強公司的持續盈利能力和整體抗風險能力,符合全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.